Gene therapy for antitumor vaccination

Seunghee Kim-Schulze, Howard L. Kaufman

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

5 Scopus citations

Abstract

Tumor immunotherapy depends on the interactions between the host, the tumor, and the immune system. Recent data suggests that priming of antigen-specific T cells alone may not be adequate for mediating regression of established tumors because of the immune inhibitory influences within the tumor microenvironment. Thus, we developed a recombinant vaccinia virus vector to express single or multiple T cell costimulatory molecules as a vector for local gene therapy in patients with malignant melanoma. This approach is feasible and generated local and systemic tumor immunity and induced objective clinical responses in patients with metastatic disease. This chapter reviews the details and major issues related to using live, replicating, recombinant poxviruses for gene delivery and antitumor vaccination within the tumor microenvironment.

Original languageEnglish
Title of host publicationGene Therapy of Cancer
Subtitle of host publicationMethods and Protocols
EditorsWolfgang Walther, Ulrike Stein
Pages515-527
Number of pages13
DOIs
StatePublished - 2009
Externally publishedYes

Publication series

NameMethods in Molecular Biology
Volume542
ISSN (Print)1064-3745

Keywords

  • Antitumor vaccination
  • melanoma
  • mmunotherapy
  • tumor antigen
  • vaccinia virus

Fingerprint

Dive into the research topics of 'Gene therapy for antitumor vaccination'. Together they form a unique fingerprint.

Cite this